It is known that hyperprolactinemia in adolescence is a rare cause of delayed or arrested puberty and growth disturbance. We studied the case of a 15-year-old girl with hyperprolactinemia, obesity, short stature and primary amenorrhea.
were taken. She was first seen at the age of 15 years and 6 months because of obesity. Her body weight was 57.3 kg (obesity index 34.1%). In addition, she was of short stature with a height of 145.6 cm (-2.3SD). Pubertal stages according to Tanner were axillary hair IV, public hair IV and breast V. Lungs, heart and abdomen showed nothing in particular. There were no gynecological abnormalities in the internal and external genital organs. Slight depression of the inner isopter of the left eye was noted. Her intelligence quotient (IQ) was 114. Her growth curve is shown in Fig. 1 .
Laboratory Results Routine laboratory examination revealed no significant abnormalities in hematometry, hemogram, blood chemistry or urinalysis.
Bone age was 14.3 years (TW2 standardized for Japanese) at her chronological age of 15.6 years. Her karyotype was 46, XX.
The endocrinological data are shown in Table 1. Serum hormone levels of the thyroid, parathyroid, adrenal cortex and gonads were within the normal range, but serum prolactin noticeably increased at 328 ng/ml.
In the oral glucose tolerance test, the time course of the blood sugar level was normal except at 30 min,, but the serum insulin level was high throughout the test. The serum prolactin level constantly remained high during insulin + TRH + LH-RH infusion, indicating no reaction to TRH stimulation ( Table 2) .
The sella turcica seemed slightly flattened on plain X-ray film. The plain and enhanced CTs were normal, but the pituitary stalk was shifted to the right on MRI (Fig. 2) . No signs which suggested the presence of a tumor mass were noted on either CT or MRI. No abnormal uptake was found on the systemic gallium scintigram.
Clinical course
The clinical course is shown in Fig. 3 . Two weeks oral administration of bromocriptine mesilate (BCM) at a dose of 2.5 mg/day was initiated, and the serum prolactin level decreased from 328 to 46.1 ng/ml, but galactorrhea persisted. Subsequently, the dose of BCM was gradually increased, and two months after the initiation of treatment, when the serum prolactin level decreased to 16.1 ng/ml, galactorrhea completely disappeared.
Four months later, when the dose of BCM reached 7.5 mg/day, menarche occurred.
Discussion
Hyperprolactinemia due to a prolactin secreting pituitary adenoma is now a well recognized cause of secondary amenorrhea in women. Such patients often respond well to orally active dopamine agonists such as BCM, which usually lead to normal serum prolactin levels and normal gonadal function. In the majority of cases, shrinkage of the adenoma occurs, even in Table  2 Endocrinological tests the presence of a large extrasellar extension. We saw hyperprolactinemia in a 15-year-old girl with primary amenorrhea, obesity and short stature. It was suggested that she had a prolactin-producing microadenoma, because brain imaging tests failed to show evidence of a tumor mass. It was also assumed that her hyperprolactinemia began at about 13 years of age , judging from the onset of her galactorrhea . encephalography, and the other five had microadenomas.
In the brain tumor registration in Japan between 1969 and 1981, 3,152 cases were registered under age 14 and only 36 (1.1%) of them had pituitary adenoma (2) . Among all the cases of prolactinoma only 0.47% of them were under age 20. Pre-and peripubertal cases of prolactinoma are therefore rare. We should therefore observe such cases very carefully, as they may reveal certain clinical features which are specific to their age and are not fully understood.
We now discuss the causes of her short stature.
Although we cannot fully exclude the possibility that her short stature may be simply explained by a constitutional (non-pathological) process, her height seems to deviate from her own growth channel at 13 years of age when galactorrhea occurred coincidentally. Jungmann et al. (3) suggested that GH secretion is impaired at the pituitary level by feedback stimulation of an inhibitory dopaminergic mechanism by prolactin excess. Howlett et al. (1) found impaired GH secretion in eight out of 14 cases of prolactinoma, and GH responses improved with bromocriptine in eight cases. In the present case, however, there seems to be no definite evidence of subnormal GH secretion, whereas slightly low plasma IGF-1 (1.82 U/ml) was noted when compared with the levels after therapy.
Irrespective of its real cause, growth disturbance is a clinically important feature in childhood prolactinoma.
Hyperprolactinemia is known to be associated with a high frequency of obesity (4). As not only growth disturbance and galactorrhea but also obesity started simultaneously at about 13 years of age in the present case ( Fig. 1) , hyperprolactinemia may also be causally related to obesity . Improvement in obesity after the induction of therapy also supports this view, but the pathogenesis of this obesity is still unclear.
In this case, her puberty started with breast development at ten years of age and reached nearly adulthood on appearance, but she had not had menarche.
We guess that her hyperprolactinemia had already been present by that time. It appears that hyperprolactinemia can cause several different symptoms according to the different times of onset of hyperprolactinemia, and there include delayed puberty, arrested puberty, primary amenorrhea and secondary amenorrhea.
Medical treatment with BCM was effective in the present case, though therapeutic results have seldom been reported in childhood prolactinoma with BCM, especially when microadenoma is suspected.
In summary, prolactinoma in adolescence is a rare cause of delayed or arrested puberty, and it may also cause short stature and/or obesity. Furthermore, it may be effectively managed by medical therapy.
All clinicians who see patients with these symptoms should therefore be aware of the possibility of this diagnosis.
